Philadelphia, June 4th, 2019 – CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap project recently launched by Feldan Therapeutics (Feldan). Amgen and Takeda will be contributing to this research project marking their first involvement in a CQDM-funded project since joining the consortium in 2018.
The funds totaling $1.2 M from the Quantum Leap project, will be used to optimize the Feldan Shuttle, Feldan’s novel intracellular delivery technology. The work will be done in collaboration with Dr Frédéric Calon from CHU du Québec – Université Laval, an expert in in vivo analysis of drug availability, toxicity and pharmacokinetics. This technology overcomes many of the barriers that in the past have precluded intracellular delivery of antibodies and peptides, thereby considering new avenues to target diseases with new treatment methods.
CQDM’s support for this project is made possible by the contribution of Feldan, the Ministry of Economy and Innovation (MEI) of the Government of Quebec, as well as funding of its industrial members: Sanofi, GlaxoSmithKline (GSK), Janssen, and now Amgen and Takeda. This brings to five the number of leading pharmaceutical organizations funding this project, demonstrating the interest and potential value of Feldan’s technology. The pharma’s involvement also brings expertise through the mentorship program. In fact, this program allows the pharma organizations to nominate a senior scientist from their global organization to mentor the research team and ensure that the developed technology will address market and medical needs.
“We are delighted to support this project”, stated Philip Tagari, Amgen’s Vice President of Therapeutic Discovery. “Amgen’s biotechnology products originating from our Canadian laboratories could benefit significantly from Feldan’s novel drug delivery technologies, which is an example of the important innovation coming from Quebec’s Life Sciences sector”. “CQDM is a unique and very effective Government-Industry partnership consortium,” added Francesco Di Marco, Vice President and General Manager of Amgen Canada. “We are looking forward to continuing our interactions with CQDM in order to develop and access research and innovation for the benefit of patients everywhere”.
“As one of Canada’s fastest-growing pharmaceutical companies, continuing our participation in CQDM and supporting initiatives like the Quantum Leap project underscores the importance of Takeda’s commitment to supporting a strong Life sciences sector in Quebec”, said Gamze Yüceland, General Manager of Takeda Canada. “Feldan’s innovative technologies are a remarkable example of how Government and industry collaboration not only strengthens the Quebec Life sciences sector but holds the promise to bring better health to patients”.
“Our team is proud that world-class leaders such as Amgen and Takeda chose to join us in our efforts to further characterize and enhance intracellular delivery using the Feldan Shuttle”, said François-Thomas Michaud, Chief Executive Officer and Co-founder of Feldan. “We are convinced that the work and business opportunities that will arise from this consortium will further open doors to the use of our technology in the development of innovative treatments addressing unmet medical needs”.
“CQDM was very excited to welcome Amgen and Takeda recently among its pharmaceutical members. When joining our consortium, they gained privileged access to a wealth of innovative biopharmaceutical research projects. We are very pleased that they have identified a first project that fits their corporate focus. This demonstrates the value of CQDM’s collaborative innovation approach to develop better treatments for patients”, said Diane Gosselin, President and CEO of CQDM.
“Support for this project attests to the enormous potential of the technology developed by the Québec firm Feldan Therapeutics. The pharmaceuticals involved will contribute not only financing, but solid expertise in drug development through the CQDM’s mentoring program. There is no doubt that these partnerships will generate significant spin-offs. We hope to attract $4 billion in private investments by 2022 to ensure the long-term growth of our life sciences industry. This announcement is a perfect indication that we are on the right track,” Pierre Fitzgibbon, Minister of Economy and Innovation, stated.